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Two non-structural proteins, V and W, are 
expressed from alternative reading frames 
in the P gene.1 The V protein functions 
as a species-specific alpha/beta interferon 
antagonist,2,3 whereas the function of the 
W protein remains unclear. The viral poly-
merase initiates at a single promoter and 
copies each gene into a separate mRNA 
using short gene-end and gene-start tran-
scription signals that flank each gene.
NDV strains are classified into three 
pathotypes depending on their virulence 
in chickens: velogenic (high virulence), 
mesogenic (medium virulence) and len-
togenic (low virulence). An important 
virulence determinant is the amino 
acid sequence of the protease cleavage 
site in the F protein,4 whose cleavage is 
essential for infectivity.5,6 Velogenic and 
mesogenic strains contain multiple basic 
amino acid residues at this position which 
together function as a recognition sequence 
for ubiquitous subtilisin-like proteases. 
However, lentogenic strains contain fewer 
basic amino acids at this position and as a 
result cleavage of their F proteins depends 
on trypsin-like proteases, which are con-
fined to the respiratory and intestinal 
tract. Consequently, only mesogenic and 
velogenic strains are capable of causing 
systemic infection. Lentogenic strains are 
commonly used worldwide for the control 
of NDV in poultry.
The availability of an NDV reverse-
genetics system has opened up ways to 
use NDV as a vaccine vector for the con-
trol of other diseases in poultry as well as 
mammals.4,7,8 The system (Fig. 1) includes 
a plasmid encoding a full-length anti-
sense copy of the viral RNA and expres-
sion plasmids that provide the NP, P and 
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Newcastle disease virus (NDV) is an avian virus that is being evalu-
ated as a vaccine vector for the delivery 
of foreign genes in mammals. The use 
of NDV as a vaccine vector in these spe-
cies offers two major advantages. First, 
NDV is highly attenuated in mammals, 
rendering its use inherently safe. Second, 
mammals lack pre-existing NDV immu-
nity, which minimizes the risk of vac-
cination failure. NDV-vector vaccines 
are generally administered to mammals 
via the respiratory route. We recently 
showed that intramuscular vaccination 
with NDV-based Rift Valley fever virus 
(RVFV) vaccines provides complete pro-
tection in mice and induces neutralizing 
antibodies in sheep and cattle, the main 
target species of RVFV. Here, we discuss 
the use of NDV as a vaccine vector for 
applications in mammalian livestock 
with an emphasis on the vaccination 
route. We also report the results of novel 
experiments that underscore our notion 
that vaccination via a parenteral route 
is more effective than immunization via 
the respiratory route.
NDV-based Vector Vaccines
Newcastle disease causes severe eco-
nomic losses in the poultry industry. The 
causative agent, Newcastle disease virus 
(NDV) belongs to the Avulavirus genus 
of the Paramyxoviridae family. The NDV 
genome is a negative-sense RNA mol-
ecule that encodes six structural proteins: 
nucleoprotein (NP), phosphoprotein (P), 
matrixprotein (M), fusionprotein (F), 
hemagglutinin-neuraminidase (HN) and 
RNA-dependent RNA polymerase (L). 
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Our laboratory is evaluating NDV as 
a vaccine vector for the control of RVFV 
in livestock. We use the lentogenic LaSota 
strain for the production of these vac-
cines.4 In a first study, calves were immu-
nized via either the intranasal (IN) or the 
intramuscular (IM) route with a recombi-
nant NDV that produces the RVFV Gn 
protein. Surprisingly, antibody responses 
against both the vector and the Gn pro-
tein were detected after IM delivery but 
not after delivery via the IN route.16 In a 
subsequent study, we showed that immu-
nization via the IM route with a recombi-
nant NDV that produces both the RVFV 
Gn and Gc proteins protects mice against 
RVFV challenge infection. Importantly, 
a single vaccination with this vaccine was 
sufficient for the induction of neutraliz-
ing antibodies in sheep, the main target 
species of RVFV.17 Thus, IM inoculation 
with our NDV-based experimental RVFV 
vaccines elicits high levels of antibodies in 
both sheep and cows and elicits protective 
immunity in mice.16,17
It was, however, unexpected to find that 
IN inoculation of calves did not result in 
vector vaccines. From these studies, it was 
concluded that NDV replicates poorly in 
the upper respiratory tract of primates 
due to the relatively low temperature 
at this site, compared to the body tem-
peratures of birds, the natural hosts of 
NDV.12 The main interest of the authors 
of this work, is to develop human vac-
cines for emerging pathogens such as the 
SARS coronavirus.11 For application of 
NDV-based vector vaccines in humans, 
delivery to the lower respiratory tract can 
indeed be realized by using innovative 
nebulizers. However, for mass applica-
tions in livestock, the use of nebulizers 
is not a practically feasible approach. We 
were therefore interested in evaluating 
immune responses elicited by IN admin-
istration only. Furthermore, regarding 
the hypothesis of DiNapoli et al.12 we 
also considered the possibility that deliv-
ery of NDV by parenteral immunization 
(i.e., administration by any route other 
than the alimentary or respiratory tract) 
could provide the virus with the optimal 
temperature for replication, resulting in 
improved immunogenicity.
L proteins. Expression of the viral RNA 
is driven by T7 polymerase that is either 
supplied by a recombinant pox virus4 or 
a stable cell line.7 After rescue of small 
amounts of virus from transfected cells 
efficient propagation of the virus can be 
performed in embryonated hens’ eggs. 
By introducing foreign genes flanked by 
dedicated gene-start and gene-end tran-
scription signals in the full-length cDNA, 
recombinant NDV-based vectors can be 
produced.9
Effect of Administration Route  
on Vaccine Efficacy
NDV-vectored vaccines as well as other 
types of paramyxovirus-based vaccine 
vectors are generally administered via the 
respiratory route, by which they generally 
show good immunogenicity.10-15 A com-
bined intranasal/intratracheal (IN/IT) 
route is most often used. Importantly, 
DiNapoli et al.12 recently demonstrated 
that delivery to the lower respiratory tract 
is required for effective immunization of 
non-human primates with NDV-based 
Figure 1. Construction of recombinant NDV strains. Protein coding regions (yellow bars) of foreign genes of interest (GOI) containing suitable addi-
tional gene-start and gene-end transcription regulation sequences are inserted between the P and M genes of plasmid pNDFL encoding the complete 
antigenomic RNA of NDV strain LaSota. The gene-start and gene-end transcription signals flanking each gene are shown as white and black boxes, 
respectively. The NDV genome can be transcribed from this plasmid using T7 promoter (T7 p) and terminator (T7 tr) sequences and a self-cleaving 
ribozyme site (R) that ensures generation of the correct 5' end. Infectious rNDV is generated by infection of cells with a fowlpox virus to supply T7 
polymerase and subsequent transfection with pNDFL and three helper plasmids that encode NP, P and L proteins under control of the CMV promoter 
(CMVp). Infectious rNDV is further propagated on embryonated hens’ eggs.
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Vaccine Safety
Although the immunogenicity of NDV-
based vector vaccines depends on virus 
replication in the inoculated mammal, 
spread in these unnatural hosts was pre-
viously shown to be highly restricted or 
even absent.10,11,19 In accordance with 
these findings, accidental NDV infections 
of mammals are rare and if these do occur 
they mostly remain subclinical.19 The 
attenuation of NDV in mammals is pri-
marily caused by the species-specificity of 
the interferon antagonist function of the 
V protein.2 Consequently, spread of both 
lentogenic and mesogenic NDV in mam-
mals is highly restricted and the use of both 
pathotypes as vaccine vectors for applica-
tion in mammals is therefore considered 
acceptable with respect to safety for the 
inoculated mammal.19 The dependence of 
lentogenic strains on trypsin-like proteases 
for infectivity makes it more difficult to 
grow these viruses in tissue culture. Since 
the introduction of foreign genes gener-
ally results in further attenuation of the 
viruses, it is sometimes challenging to pro-
duce recombinant lentogenic viruses with 
large foreign gene inserts. Therefore, vec-
tor vaccines are often based on mesogenic 
strains or lentogenic strains with modified 
F cleavage sites that confer trypsin inde-
pendence. The safety for the domesticated 
poultry industry must, however, also be 
taken into consideration when applying 
human parainfluenza virus type-3 elicited 
higher antibody titres when delivered via 
a combined IN/IT route than when the 
same vaccines were delivered via the SC 
route.12 It is important to note, however, 
that these studies differ from our studies 
with respect to the parenteral vaccination 
routes (IV, IP or SC versus IM or SC/
ID), the inoculated species (mice or non-
human primates versus cow or sheep) as 
well as the NDV strain used. Additional 
studies are clearly required to further elu-
cidate the immune responses elicited by 
NDV inoculation via different routes in 
mammals.
The NDV-based RVFV vaccines 
described in our previous studies were 
produced in embryonated hens’ eggs. The 
allantoic fluid of these eggs contained 
RVFV Gn and Gc proteins,16,17 which 
could have contributed to the elicited 
immune responses independent of virus 
replication and de novo protein pro-
duction. To gain insight into the role of 
injected proteins in the antibody response 
induced by our vaccines, we compared the 
antibody responses induced by live NDV 
with those elicited by formalin-inactivated 
NDV. The results obtained from this 
experiment (cf. Fig. 2A and B) underscore 
the notion that NDV propagation is essen-
tial for high immunogenicity in sheep and 
thereby show that co-injected protein is 
of little, if any, influence to the antibody 
response elicited.
any detectable antibody response.16 In the 
current study, we compared the immuno-
genicity of wildtype (non-recombinant) 
NDV strain LaSota when administered to 
sheep via a combined IN/IT route to two 
parenteral immunization routes: IM and 
a combined subcutaneous/intradermal 
(SC/ID) route. In addition, we compared 
the immunogenicity of live and inactivated 
NDV when delivered via these routes. Live 
NDV administered via the IM route elic-
ited significantly higher (p < 0.001 at 28 
days post primary immunization) anti-
body responses as compared to the IN/IT 
route (Fig. 2A). The antibody responses 
elicited after SC/ID immunization were 
more comparable to those obtained after 
IM immunization (Fig. 2A). Thus, in 
line with our previous studies, parenteral 
immunization with live NDV was more 
effective when compared to delivery via 
the respiratory route, in this case a com-
bined IN/IT route.
Our results seem to contrast two earlier 
studies in which parenteral NDV admin-
istration was compared with delivery via 
the respiratory tract. In the first study, 
immunization of mice with an NDV vec-
tor vaccine via the IN route induced more 
effective protective immune responses as 
compared to intravenous (IV) or intraper-
itoneal (IP) immunization.18 In another 
study, immunization with NDV-based 
vectors that either produce the SARS coro-
navirus spike protein or the HN protein of 
Figure 2. NDV-specific antibody responses in sheep inoculated with wildtype NDV strain LaSota via different immunization routes. Groups of 4 sheep 
(cross bred Texelaar x Swifter) were inoculated with live (A) or formalin-inactivated (B) NDV strain LaSota that was originally derived from the ATCC 
(VR-699). The virus was passaged three times in the allantoic cavity of 9- to 11-day-old embryonated hens’ eggs and diluted to 107 TCID50/ml in PBS 
prior to administration via the IN/IT, SC/ID or IM route in a volume of 2, 1 or 2 ml, respectively. When two different inoculation routes were used (IN/IT 
or SC/ID), the dose was equally divided between the two inoculations. Vaccinations were performed on days 0 and 21 (arrows). Serum samples were 
analyzed for the presence of NDV specific antibodies by ELISA.16 Geometric mean titres and standard deviation are shown. The Y-axis intercepts at 2.7 
10log titre, corresponding to the lowest serum dilution analyzed (500-fold).
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RNA viruses is a rare event.21 This is in 
contrast to the frequent genetic exchange 
observed between negative-strand RNA 
viruses with segmented genomes, such as 
influenza virus22 and positive-strand RNA 
viruses such as picornaviruses.23 Although 
rare, there are three recent examples that 
suggest the occurrence of recombination 
between live NDV vaccine strains that are 
used for the vaccination of poultry and 
NDV field strains.24,25 Therefore, Han et 
al.26 expressed their concern that the use of 
NDV vector vaccines in mammals would 
result in untoward recombination events. 
However, we fully support the criticism on 
this concern published by Collins et al.27 
because of the following reasons. First, 
although genetic exchange between vac-
cine strains and field strains sporadically 
occurs, it is highly unlikely that such a 
recombination event would ever result in 
a novel virus of higher virulence than the 
virus that is already circulating. Second, 
it is important to note that any possible 
recombination event would require effi-
cient replication of the vaccine virus in 
the inoculated animal. As detailed above, 
vaccination of mammals with NDV-based 
vector vaccines does not result in vire-
mia nor systemic infection, rendering the 
chance of any recombination event neg-
ligible in these species. Third, other live 
virus vaccines based on nonsegmented 
negative-strand RNA viruses, such as 
measles virus, have been used world-wide 
for a long time without any reported 
adverse events attributable to genetic 
exchange involving a vaccine strain.
In summary, we conclude that appli-
cation of NDV-based vector vaccines to 
mammalian livestock by a parenteral, 
preferably IM, route offers the advan-
tages of optimal immunogenicity, optimal 
safety and high practical feasibility for 
mass applications in livestock.
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